HomeCompareNILE vs PFE

NILE vs PFE: Dividend Comparison 2026

NILE yields 1632.65% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NILE wins by $1522521578.60M in total portfolio value
10 years
NILE
NILE
● Live price
1632.65%
Share price
$0.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1522521578.65M
Annual income
$1,358,802,192,094,537.50
Full NILE calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — NILE vs PFE

📍 NILE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNILEPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NILE + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NILE pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NILE
Annual income on $10K today (after 15% tax)
$138,775.51/yr
After 10yr DRIP, annual income (after tax)
$1,154,981,863,280,356.80/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, NILE beats the other by $1,154,981,863,258,036.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NILE + PFE for your $10,000?

NILE: 50%PFE: 50%
100% PFE50/50100% NILE
Portfolio after 10yr
$761260789.35M
Annual income
$679,401,096,060,398.10/yr
Blended yield
89.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

NILE
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NILE buys
0
PFE buys
0
No recent congressional trades found for NILE or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNILEPFE
Forward yield1632.65%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$1522521578.65M$49.6K
Annual income after 10y$1,358,802,192,094,537.50$26,258.71
Total dividends collected$1510699531.51M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NILE vs PFE ($10,000, DRIP)

YearNILE PortfolioNILE Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$173,965$163,265.31$9,153$693.39+$164.8KNILE
2$2,840,582$2,654,439.16$8,593$849.25+$2.83MNILE
3$43,546,759$40,507,336.46$8,336$1,066.78+$43.54MNILE
4$626,956,291$580,361,258.90$8,437$1,384.80+$626.95MNILE
5$8,479,854,706$7,809,011,473.99$9,013$1,875.40+$8479.85MNILE
6$107,783,962,236$98,710,517,700.67$10,306$2,680.72+$107783.95MNILE
7$1,287,916,677,762$1,172,587,838,170.00$12,820$4,101.38+$1287916.66MNILE
8$14,472,761,108,802$13,094,690,263,596.54$17,673$6,826.70+$14472761.09MNILE
9$153,008,772,484,665$137,522,918,098,247.10$27,543$12,591.86+$153008772.46MNILE
10$1,522,521,578,653,130$1,358,802,192,094,537.50$49,560$26,258.71+$1522521578.60MNILE

NILE vs PFE: Complete Analysis 2026

NILEStock

BitNile Holdings, Inc., through its subsidiaries, designs, develops, manufactures, and sells power system solutions for the defense/aerospace, industrial, automotive, telecommunications, healthcare, medical/biopharmaceutical, and textile industries in North America, Europe, the Middle East, and internationally. It offers switching and uninterruptible power supplies, power conversion and distribution equipment frequency converters, and transformer and power rectifiers; radio frequency and microwave filters, diplexers, multiplexers, detectors, switch filters, integrated assemblies, and detector logarithmic video amplifiers; and custom computer-based automated test equipment, turnkey systems, high precision calibration equipment, advance power systems, and project management and engineering solutions. The company also provides power conversion and display solutions; residential and commercial high-speed EV charging solutions; commercial loans, convertible notes, and revolving lines of credit; and virtual training courses through the LightSpeedVT platform, as well as creates various media, communications, and content, including web development, corporate communications, social media, and scripted and unscripted television. In addition, it invests in public and private companies; and various commercial and residential real estate, including hospitality, multifamily, and industrial properties, as well as operates hotels and data centers. Further, the company engages in Bitcoin mining and other activities, as well as provides digital marketing services. It sells its products directly through its sales force, as well as through independent manufacturer representatives and distributors. The company was formerly known as Ault Global Holdings Inc. and changed its name to BitNile Holdings, Inc. in December 13, 2021. BitNile Holdings Inc. was incorporated in 1969 and is headquartered in Las Vegas, Nevada.

Full NILE Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this NILE vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NILE vs SCHDNILE vs JEPINILE vs ONILE vs KONILE vs MAINNILE vs JNJNILE vs MRKNILE vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.